{"entity":{"id":"3sbio","kind":"company","name":"3SBio","aka":["Shenyang Sunshine Pharmaceutical","Sansheng Pharmaceutical"],"tldr":"3SBio is a Shenyang biologics company whose HER2 antibody inetetamab was approved in China in 2020 for HER2-positive metastatic breast cancer.","summary":"3SBio, listed in Hong Kong, is one of China's largest biologics makers, with a long-standing business in recombinant proteins (erythropoietin, thrombopoietin). In oncology its Fc-engineered HER2 antibody inetetamab (Cipterbin) was approved by the NMPA in June 2020 with vinorelbine for HER2-positive metastatic breast cancer. In May 2025 it licensed SSGJ-707, its bispecific antibody against PD-1 and VEGF, to Pfizer for development outside China, where Pfizer calls it PF-08634404; the licence took effect in July 2025 with a USD 1.25 billion upfront payment, up to USD 4.8 billion in milestones and an option for Pfizer to add China.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://www.3sbio.com"},{"label":"HKEX: licence agreement for SSGJ-707 with Pfizer coming into effect (24 July 2025)","url":"https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0724/2025072401558.pdf"},{"label":"Pfizer Form 10-K for 2025 (SEC)","url":"https://www.sec.gov/Archives/edgar/data/78003/000007800326000026/pfe-20251231.htm"}],"tags":["ctgov-sponsor","china"],"related":[],"cancers":["breast-her2-positive"],"sections":[],"technologies":["monoclonal-antibody"],"targets":[],"drugs":["inetetamab","ssgj-612","ssgj-705","ssgj-706","pf-08634404"],"companies":["pfizer"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07008703","nct07171606","nct07022002","nct07646626"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Freshened 29 October 2026: Pfizer licence terms confirmed from Pfizer's 2025 Form 10-K and 3SBio's HKEX announcements of 20 May and 24 July 2025. 3SBio was not acquired; its 2025-2026 HKEX filings also propose a separate Hong Kong listing of its subsidiary Mandi, which was not read further."],"hq":"Shenyang, China","country":"CN","companyType":"biotech","website":"https://www.3sbio.com","ticker":"1530.HK","stage":"public","investors":[],"funding":[]},"route":"/companies/3sbio/","neighbours":{"cancer":[{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"}],"technology":[{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"}],"drug":[{"id":"inetetamab","kind":"drug","name":"Inetetamab","route":"/drugs/inetetamab/"},{"id":"pf-08634404","kind":"drug","name":"PF-08634404","route":"/drugs/pf-08634404/"},{"id":"ssgj-612","kind":"drug","name":"SSGJ-612","route":"/drugs/ssgj-612/"},{"id":"ssgj-705","kind":"drug","name":"SSGJ-705","route":"/drugs/ssgj-705/"},{"id":"ssgj-706","kind":"drug","name":"SSGJ-706","route":"/drugs/ssgj-706/"}],"company":[{"id":"pfizer","kind":"company","name":"Pfizer (incl. Seagen)","route":"/companies/pfizer/"}],"trial":[{"id":"nct07233850","kind":"trial","name":"A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers","route":"/trials/nct07233850/"},{"id":"nct07171606","kind":"trial","name":"A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer（NSCLC） Patients","route":"/trials/nct07171606/"},{"id":"nct07008703","kind":"trial","name":"Phase I Study of sss40 Injection for Moderate-to-Severe Bone Metastatic Cancer Pain","route":"/trials/nct07008703/"},{"id":"nct07022002","kind":"trial","name":"SSGJ-705 Monotherapy and Combination Therapy in Advanced HER2-Expressing Solid Tumors","route":"/trials/nct07022002/"},{"id":"nct07646626","kind":"trial","name":"SSGJ-705 Plus SSGJ-612 ± Chemotherapy in Advanced HER2-Expressing Solid Tumors","route":"/trials/nct07646626/"},{"id":"nct06980272","kind":"trial","name":"SSGJ-707 in Advanced Non-Small Cell Lung Cancer","route":"/trials/nct06980272/"}]}}